Palumbo Wealth Management LLC Has $149,000 Stock Holdings in Dynavax Technologies Corporation $DVAX

Palumbo Wealth Management LLC trimmed its holdings in shares of Dynavax Technologies Corporation (NASDAQ:DVAX) by 53.5% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 15,065 shares of the biopharmaceutical company’s stock after selling 17,332 shares during the period. Palumbo Wealth Management LLC’s holdings in Dynavax Technologies were worth $149,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also recently bought and sold shares of DVAX. Invesco Ltd. increased its stake in Dynavax Technologies by 33.8% in the 1st quarter. Invesco Ltd. now owns 2,207,631 shares of the biopharmaceutical company’s stock valued at $28,633,000 after buying an additional 558,046 shares during the period. Cubist Systematic Strategies LLC increased its stake in shares of Dynavax Technologies by 237.4% in the first quarter. Cubist Systematic Strategies LLC now owns 656,541 shares of the biopharmaceutical company’s stock worth $8,515,000 after acquiring an additional 461,980 shares during the last quarter. Woodline Partners LP raised its holdings in shares of Dynavax Technologies by 48.4% during the first quarter. Woodline Partners LP now owns 1,178,763 shares of the biopharmaceutical company’s stock worth $15,289,000 after acquiring an additional 384,288 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. acquired a new stake in Dynavax Technologies during the first quarter valued at $4,370,000. Finally, Walleye Capital LLC boosted its position in Dynavax Technologies by 50,734.1% during the first quarter. Walleye Capital LLC now owns 266,879 shares of the biopharmaceutical company’s stock valued at $3,461,000 after purchasing an additional 266,354 shares during the last quarter. 96.96% of the stock is owned by hedge funds and other institutional investors.

Dynavax Technologies Stock Performance

DVAX opened at $9.73 on Friday. The company has a debt-to-equity ratio of 0.45, a quick ratio of 6.01 and a current ratio of 6.65. The company has a market cap of $1.14 billion, a PE ratio of -21.15 and a beta of 1.24. The stock has a 50-day moving average of $10.41 and a 200-day moving average of $10.83. Dynavax Technologies Corporation has a 52-week low of $9.20 and a 52-week high of $14.63.

Dynavax Technologies (NASDAQ:DVAX) last posted its earnings results on Thursday, August 7th. The biopharmaceutical company reported $0.14 earnings per share for the quarter, topping the consensus estimate of $0.12 by $0.02. Dynavax Technologies had a positive return on equity of 5.10% and a negative net margin of 16.67%.The firm had revenue of $95.44 million during the quarter, compared to analyst estimates of $87.55 million. As a group, equities research analysts forecast that Dynavax Technologies Corporation will post 0.32 earnings per share for the current fiscal year.

Insider Activity

In other news, Director Scott Dunseth Myers bought 3,800 shares of the stock in a transaction that occurred on Friday, August 22nd. The shares were acquired at an average cost of $10.82 per share, for a total transaction of $41,116.00. Following the purchase, the director owned 35,004 shares of the company’s stock, valued at $378,743.28. This represents a 12.18% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 2.98% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on the company. JMP Securities reaffirmed a “market outperform” rating and set a $32.00 price target on shares of Dynavax Technologies in a research note on Friday, August 22nd. Wall Street Zen raised shares of Dynavax Technologies from a “hold” rating to a “buy” rating in a research report on Saturday, August 9th. Three equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $24.33.

About Dynavax Technologies

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.